Program
vonoprazan
Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.
Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 310 open or running | phase 4since Feb 8, 2016 | Sep 16, 2011 | none ahead |
| Phathom Pharmaceuticals | 142 open or running | phase 3since Oct 10, 2019 | Oct 10, 2019 | Oct 20, 2027phase 3 · NCT07752407 |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Nov 14, 2021 | Nov 14, 2021 | none ahead |
| Hanlim Pharm. | 10 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
Also a collaborator on its studies: richmond-pharmacology-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 34 studies since Sep 16, 2011.
- Jan 19, 2021Phase 1 study in Healthy ParticipantsPhathom Pharmaceuticals · NCT04729101 · 44 enrolled · United States
- Feb 12, 2021Phase 1 study in Helicobacter PyloriTakeda · NCT04753437 · 44 enrolled · China
- Mar 11, 2021Phase 2 study in HeartburnPhathom Pharmaceuticals · NCT04799158 · 458 enrolled · United States
- Nov 14, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05135793 · 29 enrolled · Egypt
- Jan 4, 2022Phase 3 study in HeartburnPhathom Pharmaceuticals · NCT05195528 · 776 enrolled · United States
- Apr 18, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05343364 · 24 enrolled · United States
- May 4, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05366738 · 27 enrolled · United States
- Oct 24, 2023Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT06106022 · 22 enrolled · United States
- Apr 25, 2024Phase 1 study in HeartburnPhathom Pharmaceuticals · NCT06391177 · 15 enrolled · United States
- Oct 14, 2024Hanlim Pharm.'s first study: phase 1 study in Stomach UlcerNew to Hanlim Pharm.Hanlim Pharm. · NCT06642987 · 30 enrolled · Korea, Republic of
- Feb 14, 2025Phase 1 study in Healthy VolunteersPhathom Pharmaceuticals · NCT06831344 · 25 enrolled · United States
- Feb 24, 2025Phase 2 study in Eosinophilic EsophagitisPhathom Pharmaceuticals · NCT06851559 · 95 enrolled · United States
- Dec 9, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Erosive GastritisNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07278349 · 28 enrolled · Jordan
- Aug 3, 2026Phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407 · 500 planned · United States
Ahead
- Oct 20, 2027Primary completion: phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07752407Gastroesophageal Reflux · United States | 3 | Recruiting | Phathom Pharmaceuticals | Oct 20, 2027 | 500 |
| NCT07278349Erosive Gastritis · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Oct 4, 2025 | 28 |
| NCT06851559Eosinophilic Esophagitis · United States | 2 | Active, not recruiting | Phathom Pharmaceuticals | Sep 11, 2026 | 95 |
| NCT06831344Healthy Volunteers · United States | 1 | Completed | Phathom Pharmaceuticals | Apr 5, 2025 | 25 |
| NCT06642987Stomach Ulcer · Korea, Republic of | 1 | Completed | Hanlim Pharm. | Nov 3, 2023 | 30 |
| NCT06391177Heartburn · United States | 1 | Completed | Phathom Pharmaceuticals | Sep 13, 2024 | 15 |
| NCT06106022Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | Apr 16, 2024 | 22 |
| NCT05366738Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | Jul 1, 2022 | 27 |
| NCT05343364Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | May 30, 2023 | 24 |
| NCT05195528Heartburn · United States | 3 | Completed | Phathom Pharmaceuticals | Nov 21, 2022 | 776 |
| NCT05135793Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Feb 2, 2021 | 29 |
| NCT04799158Heartburn · United States | 2 | Completed | Phathom Pharmaceuticals | Dec 16, 2021 | 458 |
| NCT04753437Helicobacter Pylori · China | 1 | Completed | Takeda | Sep 27, 2021 | 44 |
| NCT04729101Healthy Participants · United States | 1 | Completed | Phathom Pharmaceuticals | Jun 12, 2021 | 44 |
| NCT04558216Healthy Participants · United States | 1 | Withdrawn | Phathom Pharmaceuticals | Feb 7, 2021 | 0 |
| NCT04545944Healthy Volunteers · United States | 1 | Completed | Phathom Pharmaceuticals | Nov 13, 2020 | 20 |
| NCT04198363Helicobacter Pylori · China | 3 | Completed | Takeda | Nov 1, 2021 | 510 |
| NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more | 3 | Completed | Phathom Pharmaceuticals | Mar 10, 2021 | 1,046 |
| NCT04124926Erosive Esophagitis · United States, Bulgaria, Czechia and more | 3 | Completed | Phathom Pharmaceuticals | Jul 29, 2021 | 1,027 |
| NCT03808493Japanese Healthy Adult Male · Japan | 1 | Completed | Takeda | Mar 12, 2019 | 48 |
| NCT03116841Esophagitis, Peptic · Japan | 4 | Completed | Takeda | Dec 20, 2017 | 3 |
| NCT03085836Healthy Participants · China | 1 | Completed | Takeda | Aug 17, 2017 | 33 |
| NCT03050359Duodenal Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Takeda | Mar 19, 2019 | 533 |
| NCT03050307Stomach Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Takeda | Feb 19, 2020 | 234 |
| NCT02954848Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Takeda | Feb 25, 2018 | 484 |
| NCT02892409Helicobacter Pylori · Korea, Republic of | 1 | Completed | Takeda | Apr 17, 2017 | 30 |
| NCT02774902Healthy Volunteers | 1 | Completed | Takeda | Sep 2010 | 16 |
| NCT02679508Esophagitis · Japan | 4 | Completed | Takeda | Mar 5, 2022 | 208 |
| NCT02388737Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Takeda | Dec 24, 2018 | 703 |
| NCT02388724Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Takeda | Jul 27, 2017 | 481 |
| NCT02141711Gastroesophageal Reflux · United Kingdom | 1 | Completed | Takeda | Feb 2009 | 48 |
| NCT02141698Dose Finding Study | 1 | Completed | Takeda | Feb 2008 | 73 |
| NCT02123953Dose Finding Study | 1 | Completed | Takeda | Mar 2009 | 60 |
| NCT02123927Ascending Single Dose Study | 1 | Completed | Takeda | Dec 2007 | 108 |
| NCT01630746Erosive Esophagitis · Japan | 3 | Completed | Takeda | Sep 2013 | 19 |
| NCT01568398Stomach Ulcer · Japan | 3 | Completed | Takeda | Aug 2013 | 27 |
| NCT01568385Stomach Ulcer · Japan | 3 | Completed | Takeda | Sep 2013 | 30 |
| NCT01505127H. Pylori Infection · Japan | 3 | Completed | Takeda | Jun 2013 | 650 |
| NCT01474369Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Takeda | Feb 2013 | 827 |
| NCT01459367Erosive Esophagitis · Japan | 3 | Completed | Takeda | Mar 2013 | 607 |
| NCT01456260Stomach Ulcer · Japan | 3 | Completed | Takeda | 406 | |
| NCT01456247Stomach Ulcer · Japan | 3 | Completed | Takeda | Oct 2013 | 439 |
| NCT01452776Erosive Esophagitis · Japan | 3 | Completed | Takeda | Jul 2013 | 305 |
| NCT01452763Stomach Ulcer · Japan | 3 | Completed | Takeda | Apr 2013 | 621 |
| NCT01452750Stomach Ulcer · Japan | 3 | Completed | Takeda | Jun 2013 | 642 |
| NCT01452724Duodenal Ulcer · Japan | 3 | Completed | Takeda | Feb 2013 | 372 |
| NCT01452711Stomach Ulcer · Japan | 3 | Completed | Takeda | Dec 2012 | 482 |
| NCT01452698Erosive Esophagitis · Japan | 3 | Completed | Takeda | Aug 2012 | 409 |
How it is read
Names in the registry
- “TAK-438”, 32 entries
- “Vonoprazan”, 20 entries
- “Vonoprazan (Reference)”, 1 entry
- “Vonoprazan Tablets”, 1 entry
- “VOQUEZNA® Tablets”, 1 entry
Conditions, from the studies’ own filings
- Esophagitis, 9 studies
- Stomach Ulcer, 9 studies
- Gastroesophageal Reflux, 7 studies
- Heartburn, 3 studies
- Duodenal Ulcer, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.